**G6PD Genotyping Algorithm for Therapeutic Drug Recommendations**

*Variants of uncertain significance (VUS) may be identified. If a VUS is identified, a WHO Class will not be assigned and enzyme studies are recommended.

† WHO Class I Variant: Severe G6PD enzyme deficiency (<10% activity) and chronic nonspherocytic hemolytic anemia (CNSHA)

WHO Class II/III Variant: Deficient G6PD enzyme activity (10%-60% activity)

WHO Class IV Variant: Normal G6PD enzyme activity

---

**G6PDB / Glucose-6-Phosphate Dehydrogenase (G6PD) Full Gene Sequencing**

- Female (heterozygous)
- Male (hemizygous)
- Female (homozygous/compound heterozygous)

---

**Therapeutic Recommendation:**

- No G6PD-related contraindication of drugs/compounds
- Contraindication for drugs associated with hemolytic anemia in G6PD-deficient patients

---

**Diagnostic for G6PD deficiency:**

- Order: G6PD1 / Glucose 6-Phosphate Dehydrogenase Enzyme Activity, Blood

---

**Indeterminate-G6PD enzyme assay needed**

- Indeterminate phenotype

---

**Therapeutic Recommendation:**

- No G6PD-related contraindication of drugs/compounds
- Contraindication for drugs associated with hemolytic anemia in G6PD-deficient patients

---

© Mayo Foundation for Medical Education and Research (MFMER). All rights reserved.